Top 5 Up And Coming Companies To Invest In 2014

The following video is from Wednesday's installment of The Motley Fool's�Weekly Tech Review, in which host Chris Hill, and analysts Eric Bleeker and Lyons George take a look at the biggest stories driving the tech sector this week.

In this segment, Eric and Lyons discuss Apple's (NASDAQ: AAPL  ) ambitions around creating an "iWatch." In the past week, Apple applied for a trademark on the term iWatch in Japan, Mexico, and Taiwan, leading many to speculate as to whether the launch of an iWatch is imminent, and whether such a product would be another hit product from Apple.�

Eric discusses why any narrative around whether a watch will "save" Apple is misguided. As he says, ideas like Apple TV, iOS in the Car, and an iWatch are as much about broadening iOS out into complementary areas as they are about bottom-line padding. Looking at a watch purely on bottom-line impact fails to capture what Apple's ambitions are with products its currently exploring.�

The two also discuss whether Apple signing up for trademarks makes any product launch imminent, and the possible success of watch concepts from Microsoft� (NASDAQ: MSFT  ) and Android companies like�Sony� (NYSE: SNE  ) and Samsung.�

Top 5 Semiconductor Companies To Buy Right Now: Intuit Inc.(INTU)

Intuit Inc. provides business and financial management solutions for small and medium-sized businesses, consumers, accounting professionals, and financial institutions primarily in the United States, Canada, India, Singapore, and the United Kingdom. The company offers QuickBooks financial and business management software and services, technical support, financial supplies, and Web site design and hosting services for small and medium-sized businesses; and payroll products and services, as well as merchant services comprising credit and debit card processing, electronic check conversion, and automated clearing house services for small businesses. It also provides TurboTax income tax preparation products and services for consumers and small business owners; Lacerte and ProSeries professional tax products and services; and QuickBooks Premier Accountant Edition and the QuickBooks ProAdvisor Program for accounting professionals. In addition, the company offers outsourced online financial management solutions for banks and credit unions; Quicken personal finance products and services; Mint.com online personal finance services; and Intuit Health online patient-to-provider communication solutions. It sells its products and services through various sales and distribution channels, including Websites, promotions, retail channels, and call centers, as well as through alliance partners, principally consisting of banks, credit unions, and securities and investment firms. The company was founded in 1983 and is headquartered in Mountain View, California.

Advisors' Opinion:

• [By Shauna O'Brien]

  Morgan Stanley reported on Wednesday that it has downgraded financial management solution provider Intuit Inc. (INTU).

  The firm has cut its rating on INTU to “Underweight,” and has given the company a $62 price target. This price target suggests a 6% decline from the stock’s current price of $66.30. This downgrade reflects the company’s slowing growth of its tax business.

  Intuit shares were mostly flat during pre-market trading Wednesday. The stock is up 11% YTD.

Top 5 Up And Coming Companies To Invest In 2014: Unisys Corporation (UIS)

Unisys Corporation provides information technology (IT) services, software, and technology that solve mission-critical problems for clients worldwide. It operates in two segments, Services and Technology. The Services segment provides outsourcing services, including management of customers� data centers, computer servers, and end-user computing environments, as well as specific business processes; systems integration and consulting services, such as assessing the security and cost effectiveness of clients� IT systems and enabling them to design, integrate, and modernize mission-critical applications; infrastructure services consisting of design, warranty, and support services for its customers� IT infrastructure, such as networks, desktops, servers, and mobile and wireless devices; and maintenance services. The Technology segment designs and develops servers and related products consisting of enterprise-class servers, which comprise the ClearPath family of servers and t he ES7000 family of Intel-based servers, as well as operating system software and middleware; and provides data center, infrastructure management, and cloud computing offerings for clients to virtualize and automate their data-center environments. The company serves public sector; financial services; and other commercial markets comprising communications and transportation. Unisys Corporation markets its products and services primarily through direct sales force, as well as through distributors and alliance partners. Unisys Corporation was founded in 1886 and is headquartered in Blue Bell, Pennsylvania.

Advisors' Opinion:

• [By Lauren Pollock]

  Unisys Corp.(UIS) narrowed its loss in the third quarter as a decrease in costs partially offset a decline in revenue. Shares of the company, which provides information-technology services and software for commercial and government clients, fell 8.1% to $23.99 in premarket trading as its earnings and revenue came in below analysts’ expectations.

• [By Rich Duprey]

  Holders of�Unisys' (NYSE: UIS  ) Series A�6.25% mandatory convertible preferred stock will receive a dividend of�$1.5625�per share. The dividend is payable on June 1 to shareholders of record at the close of business on May 15, the company announced this week.

• [By Evan Niu]

  What: Shares of Unisys (NYSE: UIS  ) have popped by as much as 13% today after the company reported earnings.

  So what: Revenue of $859 million crushed the consensus estimate of $838 million. The bottom line also beat, but by less. Unisys posted non-GAAP earnings per share of $0.91, slightly ahead of the $0.90-per-share forecast.

• [By Monica Gerson]

  Unisys (NYSE: UIS) is estimated to post its Q3 earnings at $0.40 per share on revenue of $854.13 million.

  Harley-Davidson (NYSE: HOG) is expected to report its Q3 earnings at $0.73 per share on revenue of $1.17 billion.

Top 5 Up And Coming Companies To Invest In 2014: Walter Bau AG (WTB)

Walter Bau AG is an international construction group based in Augsburg, southern Germany. The Company's core construction-related services are planning, financing, project development and facilities management. It is active in the fields of turnkey construction, civil engineering, international construction and transportation infrastructure. Its subsidiary, DYWIDAG-Systems International markets the Company's products and systems worldwide, particularly in the field of post-tensioning and geotechnics, as well as special civil engineering processes. Walter Bau also provides operation and financing solutions, as well as developing commercial and residential real estate projects. Facilities Management is offered by DYWIDAG Service GmbH. Its Logistics Competence Center in Augsburg bundles the Company's Germany-wide activities as a general contractor in the planning, construction and support of distribution centers. The Company commenced insolvency proceedings in April 2005. Advisors' Opinion:

• [By Namitha Jagadeesh]

  BHP Billiton Ltd. (BHP) and Rio Tinto Group, the world�� biggest mining companies, fell at least 3 percent. Whitbread Plc (WTB) dropped 2.8 percent after UBS AG downgraded the owner of the Costa Coffee chain. British Land Co., the U.K.�� second-largest real estate investment trust, advanced 1.2 percent after saying it bought commercial property in London for 470 million pounds ($707 million).

• [By Sofia Horta e Costa]

  Whitbread Plc (WTB) added 4.1 percent to 3,114 pence, its largest advance since September 2012. Oriel Securities Ltd. raised its rating on the shares to buy from hold, citing improvement in the U.K. hotel market.

Top 5 Up And Coming Companies To Invest In 2014: Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc. (Oncolytics), incorporated on April 2, 1998, is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. As of December 31, 2011, the United States National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) were sponsoring part of its clinical trial program.

The Company�� clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. On December 31, 2011, the Company had two wholly owned subsidiaries, Oncolytics Biotech (Barbados) Inc. (OBB) and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are wholly owned subsidiaries of OBB.

Advisors' Opinion:

• [By Maxx Chatsko]

  T-VEC is not your traditional biologic drug. It is actually a bioengineered form of the herpes virus that, once injected into cancerous tumors, replicates, and produces an immune-stimulating protein that puts a bulls eye on cancer cells throughout the body. Despite its promise and intriguing mechanism of action, T-VEC is not in further development at Amgen. However, Oncolytics (NASDAQ: ONCY  ) has shown promising results for its bioengineered form of reovirus called Reolysin. Initial phase 3 results showed that 86% of patients taking the drug had reduced tumor mass or growth after six weeks of treatment. �

• [By Sean Williams]

  With this in mind, I feel it'd be prudent of biotech-savvy investors to give Oncolytics Biotech (NASDAQ: ONCY  ) a closer look.

  The big risks
  I'm quite aware that there are a lot factors that'd raise a red flag with Oncolytics. Similar to Affymax, you could say that Oncolytics has put all of its eggs in one basket with its lead experimental drug, reolysin. According to Oncolytics' website, including its U.K., Canadian, and U.S. studies, reolysin as either a monotherapy or combination therapy is the basis for all 31 clinical trials! Obviously, if reolysin proves ineffective or unsafe, Oncolytics is going to be a world of hurt.